Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib and Tislelizumab with CCRT in Locally Advanced NSCLC
NCT07086456Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2025
- Primary completion
- Jul 2029
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib, tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Started Jul 2025; status: recruiting.
02
Drugs
surufatinibtislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07086456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07086456.